The Section of Gastroenterology and Hepatology had another successful year. With more than 160 papers in scientific journals and more than $8.9 million in research funding in 2019, the Section remains a leader in research in gastrointestinal and liver diseases. The Section continues to be the clinical home for the NIH-funded Digestive Disease Center, one of 17 federally funded centers focusing on research in GI diseases. Section members are in key leadership positions, ranging from serving in the Faculty Senate at the College level to holding the office of the President of the American Gastroenterological Association at the national level. The Section also serves as the home for the Clinical Gastroenterology and Hepatology, one of the major clinical journals in the field.

Our top-notch faculty provides high-quality, compassionate healthcare at Baylor St. Luke’s Medical Center (BSLMC), Ben Taub General Hospital, and Michael E. DeBakey Veterans Affairs Medical Center. In 2019, BSLMC ranked #22 in the nation for Gastroenterology. We introduced several innovations in our practices, including cutting-edge, advanced endoscopic procedures and multidisciplinary treatment of complex GI disorders. Collectively, our faculty performed 22,564 procedures across our three hospitals in 2019.

We continue to play an important role in advancing our understanding of digestive and liver diseases and training future clinicians and researchers. The Section hosted two highly successful CME-accredited courses this past year. More than 100 participants attended the inaugural Board Review Course in September 2018. Over 200 participants attended the 19th Annual Baylor GI and Hepatology Course in March 2019.

This annual report outlines some of the achievements and recognitions received during 2019.

Fasiha Kanwal, M.D., MSHS, AGAF
Professor of Medicine
Chief, Gastroenterology and Hepatology

**HIGHLIGHTS**

**Awards**

- **Hashem El-Serag, M.D., M.P.H** was elected to serve as the President of the American Gastroenterological Association
• **RUBEN HERNAEZ, M.D., M.P.H., PH.D., AND DR. AVINASH KETWAROO** were selected for the 2019-2020 AGA Future Leaders Program

• **Maria Ellionore Jarbrink-Sehgal, M.D., Ph.D.** received PhD degree from Karolinska Institute

• **Fasiha Kanwal, MD, MSHS** served as Editor-in-Chief, *Clinical Gastroenterology and Hepatology (CGH)* and the Chair of the AASLD Practice Metrics Committee Member

• **Mohamed Othman, M.D.** was selected as the Special Section Editor for Focal Points Section of Gastrointestinal Endoscopy

• **WAQAR QURESHI, MD** served as the Course Director for American Society for Gastrointestinal Endoscopy at DDW

• **Milena Gould Suarez, M.D.**, was nominated to join the Selection Committee for Baylor’s Norton Rose Fulbright Faculty Excellence Award, and Reappointed as a PPS I/II Faculty Facilitator

**Grants**


- Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD): A Cluster Randomized Controlled Trial. PCORI; PLC-1609-36714. 01/2019 – 12/2019 (Site PI: Maya Balakrishnan)

- Risk of Hepatocellular Cancer After Virological Cure with Direct Acting Antiviral Agents in Individuals with Hepatitis C. CDMRP. 07/2019 – 06/2022  (PI: Fasiha Kanwal)

- Risk Stratification for and Early Detection of Liver Cancer. NIH; 1 U01 CA230997-01. 09/2018–08/2023  (PI: Fasiha Kanwal)

- Mechanisms of Intestinal Stem Cell Differentiation and Plasticity. NIDDK; R01-DK118904. 09/2018 – 06/2019  (PI: Noah Shroyer)


- Young Investigator Grant award from American Pancreatic Association (PI: Natalia Khalaf)

- The Effect of Dawn to Sunset Fasting on Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. 2019 Roderick D. MacDonald Research Award/Baylor St. Luke’s Medical Center (PI: Ayse Mindikoglu)

**New Programs**

The Section hosted two highly successful CME accredited Courses this past year. Over 100 participants attended the inaugural Board Review Course in September 2018. Over 200 participants attended the 19th Annual Baylor GI and Hepatology Course in March 2019.

**Other Major Accomplishments**

In 2019, BSLMC ranked #22 in the nation for Gastroenterology. We introduced several innovations in our practices, including cutting edge advanced endoscopic procedures and multidisciplinary treatment of complex GI disorders. Collectively, our faculty performed 22,564 procedures across our three hospitals in 2019. We continue to play an important role in advancing our understanding of digestive and liver diseases and training future clinicians and researchers.
Faculty

FGP
Wasif Abidi, M.D.
Suneal Agarwal, M.D.
Sharmila Anandasabapathy, M.D.
Andrea Bradford, P.h.D
Johanna Chan, M.D.
Reena Chokshi, M.D.
Elaine Hess, P.h.D.
Salmaan Jawaid, M.D.
Jason Hou, M.D.
Fasiha Kanwal, M.D.
Manreet Kaur, M.D.
Lukasz Kwapisz, M.D.
Nabil Mansour, M.D.
Temitope Osinaiya, D.H.S.c.
Mohammed Othman, M.D.
Kalpesh Patel, M.D.
Waqar Qureshi, M.D.
Rehman Sheikh, M.D.

Ben Taub – Harris Health Systems
Maya Balakrishnan, M.D.
Khushboo Munot, M.D.
Chris Pappas, M.D.
RJ Sealock, M.D.
Richa Shukla, M.D.
Melina Suarez, M.D.
Fred Sutton, M.D.
Mimi Tan, M.D.

VAMC
Rhonda Cole, M.D.

Avegail Flores, M.D.
David Graham, M.D.
Clark Hair, M.D.
Ruben Hernaez, M.D.
Nisreen Husain, M.D.
Khozema Hussain, M.D.
Maria-Ellinore Jarbrink-Sehgal, M.D.
Gyanprakash Ketwaroo, M.D.
Natalia Khalaf, M.D.
Yamini Natarajan, M.D.
Hoda Malaty, M.D.

BSLMC Hepatology
F. Blaine Hollinger, M.D.
Prasun Jalal, M.D.
Saira Khaderi, M.D.
Ayse Mindikoglu, M.D.
Gagan Sood, M.D.
Rise Stribling, M.D.
Norman Sussman, M.D.
John Vierling, M.D.

HSR
Yan Liu, M.S.

Research
Ru Chen, P.h.D.
Fu Loning, P.h.D.
Noah Shroyer, P.h.D.
Antone Opekun, P.A.-C.
Li Jiao, M.D.
Boris Yoffe, M.D.

Professional Organizations/Association Offices Held

Bradford, Andrea, Ph.D.
• Associate Editor, Journal of Clinical Psychology in Medical Settings

Balakrishnan, Maya, M.D.
• Member, AASLD Public Health Special Interest Group

Chen, Ru, M.D.
• Member, CSR Conflict Special Emphasis Panel
Chokshi, Reena, M.D.
- Co-Section Editor, Large Intestines Section
- Member, Women in GI Committee

Gould Suarez, Milena, M.D.
- Member, AGA Women’s Committee

Graham, David, M.D.
- Member, World Gastroenterology Organizing: Steering Committee on Early Diagnosis and Treatment of GI Cancers
- Member, World Gastroenterology Organizing Guidelines Committee 2019

Kanwal, Fasiha, M.D.
- Editor-in-Chief, Clinical Gastroenterology and Hepatology
- Chair, AASLD Practice Metrics Committee
- Member, AASLD Health Services Delivery/Public Health Special Interest Group Executive Committee
- Member, AGA Systematic Reviews and Epidemiology Abstract Review Section

Ketwaroo, Gyanprakash, M.D.
- Associate Editor, GI and Hepatology News
- Member, AGA Quality Metrics Committee
- Chair, Early Career and Trainee Committee

Hou, Jason, M.D.
- Chair, Colon Sub-Committee
- Chair, AGA GI Training Exam Committee
- Chair, American Gastroenterology Association
- Member, National VA Inflammatory Bowel Disease Technical Advisory Group Member, Crohn’s and Colitis Foundation IBD Partners Project Selection Committee Member, Executive Board: CCFA South Texas Chapter
- Member, Chapter Medical Advisory Committee Co-Chair: CCFA South Texas Chapter
- Member, Crohn’s and Colitis Foundation of American National Clinical Grant Review Committee

Jiao, Li, M.D.
- Member, WHI Ancillary Study Committee

Natarajan, Yamini, M.D.
- Member, AGA Government Affairs Committee
- Member, AGA Congressional Advocates
- Member, AGA Young Delegates
- Member, MEDVAMC Nutrition Committee
- Member, BCM GI Wellness Committee

Othman, Mohamad, M.D.
- Associate Editor, Gastrointestinal Endoscopy
- Member, ASGE Annual Program Committee
- Member, ACG Minority Affairs Committee
Qureshi, Waqar, M.D.
- Member, ASGE Educational products committee
- Member, ASGE Video Products Committee for DDW
- Member, TSGE Annual Course Education Committee

Sealock, Robert, M.D.
- Member, ASGE Annual Scientific Program Committee

**RESEARCH ACTIVITIES**

**Grants**

Agarwal, Suneal, M.D.
- A 12-Week, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial with a 4-Week Randomized Withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Participants with Diabetic Gastroparesis; Allergan Pharmaceuticals

Anandasabapathy, Sharmila, M.D.
- High Resolution Microendoscopy for the Management of Esophageal Neoplasia; NCI/NIH (R01)
- The Effectiveness of High Resolution Microendoscopy in High Grade Intraepithelial Lesions Diagnosis for People Living with HIV; NCI/NIH (R01)
- Controlling Esophageal Cancer: A Collaborative Modeling Approach; NCI/NIH
- A Low-Cost Tethered Capsule Endoscope for Esophageal Cancer Screening; NCI/NIH
- Automated, Augmented Reality High Resolution Microendoscopy for the Management of Esophageal Neoplasia; NCI/NIH (R01)
- Early Detection of Esophageal Adenocarcinoma Using a Low Cost Confocal Microendoscope with Automated Software Algorithms; Dan L Duncan Comprehensive Cancer Center

Balakrishnan, Maya, M.D.
- Introducing Palliative Care Within the Treatment of End Stage Liver Disease: A Cluster Randomized Controlled Trial; PCORI

Chen, Ru, M.D.
- Biomarkers for Early Detection of Colorectal Cancer in Ulcerative Colitis; NIH (R01)
- Early Detection of Pancreatic Cancer in Diabetics; NIH (R01)

El-Serag, Hashem, M.D.
- Baylor College of Medicine Cancer Center (BCMCC); NIH/NCI
- Research Training in Gastroenterology; NIH
- Biomarkers Profiles of HCV-Related Hepatocellular Carcinoma; NIH (R01)
- A New Lab-Based Algorithm for HCC Surveillance in Patients and Cirrhosis; NIH (R01)
- Texas Hepatocellular Carcinoma Consortium (THCCC); CPRIT
- PREVENT HCC – through Screening, Vaccination and Treatment of Viral Hepatitis; CPRIT
- Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Veterans; VA Merit

Hernaez, Ruben, M.D.
- Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis; NCI/NIH
Hou, Jason, M.D.
- Changes in Actin Dynamics Regulated by Villin and Gelsolin Are Determinants of Cell Fate and May Be Key to Gastrointestinal Inflammatory Disease; NIDDK
- Patient-Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD; AHRQ
- Patient-Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD; Crohn’s and Colitis Foundation of America; 2015 Career Development Award
- IBD Gene Mapping by Clinical and Population Subset; NIH/NIDDK
- A Phase 3B, Randomized, Controlled, Multicentre study with Oral Ferric Maltol (Feraccru) of Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anemia in Subjects with Inflammatory Bowel Disease; Shield Therapeutics PLC
- A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis; Pfizer Inc.
- A Phase 3 Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis; Abbvie Inc.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis; Janssen Research & Development, LLC
- Protocol P1-282 – A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC); Abbvie Inc.
- Effectiveness, Safety, and Patient Preferences of Infliximab Biosimilar Medications for Inflammatory Bowel Disease; VA HSR&D
- Anemia Treatment Patterns and Outcomes among a National Cohort of Patients with Inflammatory Bowel Disease; American Regent

Gould Suarez, Milena, M.D.
- H. Pylori Strains and Biomarkers in Gastric Cancer; Department of Defense
- Prevent HCC - through Screening Vaccinations and Treatment of Viral Hepatitis; CPRIT

Jalal, Prasun, M.D.
- Outcomes of a Hepatocellular Cancer Surveillance Program: A Retrospective Cohort Study

Kanwal, Fasiha, M.D.
- Center for Gastrointestinal Development, Infection and Inquiry; NIDDK
- A Personalized Surveillance Program for Hepatocellular Carcinoma; American Cancer Society Extramural Grant
- Patient Centered Care for Individuals with Advanced Liver Disease; HSR&D
- Risk Factors of Hepatocellular Cancer in Non-Alcoholic Fatty Liver Disease; CPRIT
- Cirrhosis Quality Collaborative; AASLD
- Risk Stratification for and Early Detection of Liver Cancer; NIH
- Risk of Hepatocellular Cancer After Virological Cure with direct Acting Antivirala agents in Individuals with Hepatitis C; CDMRP
Kaur, Manreet, M.D.

- Combined Phase 3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease; Pharm Rsch Association/GIL
- Entyvio® Outcomes in Real-World Bio-naive Ulcerative Colitis and Crohn’s Disease Patients (Evolve) – USA; PPD/Takeda Pharma
- A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis; Gilead
- To compare the Efficacy of Treatment with Ustekinumab or Adlimumab in Biologic Naïve Subjects with Moderately-to-Severely Active CD who have Previously Failed or were Intolerant to Conventional Therapy, as Measured by Clinical Remission at one year; JANSSEEN Research

Khalaf, Natalia, M.D.

- Acute Pancreatitis and Pancreatic Cancer: Improving Early Detection; American Pancreatic Association

Mindikoglu, Ayse, M.D.

- The Effect of Dawn to Sunset Fasting on Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease; 2019 Roderick D. MacDonald Research Award

Othman, Mohamed, M.D.

- Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Center; NIH
- A Phase 1, Single-Dose Pk and Safety Study with Ni-03 Followed by A Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study To Evaluate The Safety And Efficacy of Ni-03 Compared To Placebo In subjects With Chronic Pancreatitis; Kangen Pharmaceutical
- Multi-Center Prospective Registry Evaluation Utilizing A Double Balloon Accessory Device To Facilitate Endoscopic Polypectomy In Large Intestine; Lumendi
- Prevalence of Exocrine Pancreatic Insufficiency in Patients Presenting with Diarrhea; Abbvie Pharmaceutical
- Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma; US Biotest, Inc
- A Trial Evaluating Escalating Doses and Safety of Intracystic Injection of NANOPAC® in Subjects with Mucinous Cystic Pancreatic Neoplasm; US Biotest, Inc

Shroyer, Noah, M.D.

- Mechanisms of Intestinal Stem Cell Differentiation and Plasticity; NIDDK (R01)

Vierling, John, M.D.

- A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis and Stage 3 Liver Fibrosis; BMS
- A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis and Compensated Liver Cirrhosis; BMS
- An Open-Label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (Apd334) in Patients with Primary Biliary Cholangitis; Arena
• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis; Allergen Aurora NASH

• Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis; Intercept

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis Fibrosis; Conatus

• Early Detection of Hepatocellular Carcinoma; NIH/NCI

• A Phase 2, Pilot Study of JKB-122 to Assess Liver Test in Autoimmune Hepatitis Patients who are Refractory or Intolerant to Current Therapies; TaiwanJ

• A Randomized, Double-Blind Placebo Controlled, 2-Part, Adaptive Design, Multicenter 12-Week Study to Assess Safety, Tolerability and Efficacy of LJN452 in Patients with Non-Alcoholic Steatohepatitis; Novartis

• A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects with Hepatorenal Syndrome Type 1 (The Confirm Study); Mallinckrodt Pharmaceuticals

• A Multicentre Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Non-Alcoholic Steatohepatitis and Fibrosis; Genfit

• An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis and an inadequate response to or intolerance to ursodeoxycholic acid; CymaBay Therapeutics, Inc.

• A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor in Adults with Nonalcoholic Steatohepatitis; Shire

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection; Gilead

• Procurement of Blood Samples from Subjects with Diagnosed Nonalcoholic Steatohepatitis or Nonalcoholic Fatty Liver Disease for Use in the Development of a Liver Fibrosis Test; Prometheus

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis; Gilead Sciences, Inc.

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis; Gilead Sciences, Inc.

• A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80mg and 120mg After 12 Weeks of Treatment in Patients With Primary Biliary Cholangitis and Inadequate Response to Ursodeoxycholic Acid; GenFit
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis and Bridging (F3) Fibrosis; Gilead Sciences, Inc.

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis; Gilead Sciences

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH Cirrhosis; Conatus

• A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate Safety, Tolerability, and Pharmacodynamics of PF 05221304 Administered Daily for 16 Weeks to Adult Subjects with Non-Alcoholic Fatty Liver Disease; Pfizer

• A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase; Genkyotex

• A Phase 2 Dose Ranging, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis with or without an Inadequate Response to Ursodeoxycholic Acid; Enanta

• A Phase 2 Dose Ranging, Randomized, Double-Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Non-Alcoholic Steatohepatitis; Enanta

• An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis; CymaBay

• A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis; Intercept

• A Two-Part Randomized, Double-B/blind, Placebo-Controlled Multicenter Dose Ranging and Confirmatory Study to Assess the Safety and Efficacy of VAY736 in Autoimmune Hepatitis Patients with Incomplete Response to or Intolerance of Standard Therapy (AMBER); Novartis

• A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment; Intercept

• A Phase 2bm Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis and Compensated Liver Cirrhosis; BMS

• An Open-Label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (Apd334) in Patients with Primary Biliary Cholangitis; Arena

• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis; Allergen Aurora NASH

**Publications**

Clinical Gastroenterology and Hepatology (IF 7.896): 31

Hepatology (IF 14.079): 7
Gastroenterology (IF 20.877): 17
Medicine (Baltimore) (IF 2.133): 1
Lancet (IF 59.102): 1
Lancet: Gastroenterology (IF 12.856): 1
Alimentary Pharmacology and Therapeutics (IF 7.357): 5
Journal of Hepatology (IF 18.946): 4
Journal of Clinical Medicine (IF 5.688): 1
Cell Reports (IF 7.815): 1
Expert Review of Anti-infective Therapy (IF 3.461): 1
Transplantation (IF 4.74): 3
Metabolics (IF 3.303): 1
Kidney International Reports (IF 8.395): 1
Journal of Digestive Diseases (IF 2.819): 2
Current Opinion in Gastroenterology (IF 2.741): 1
Digestive Diseases and Sciences (IF 2.819): 10
Seminars in Plastic Surgery (IF 0.561): 2
Journal of Viral Hepatitis (IF 4.016): 2
Translational Gastroenterology and Hepatology (IF 3.925): 2
Pancreas (IF 2.675): 2
United European Gastroenterology Journal (IF 3.453): 1
Nature Reviews Clinical Oncology (IF 34.106): 1
Cellular and Molecular Gastroenterology & Hepatology (IF 6.850): 1
Gut (IF 17.943): 2
Surgical Endoscopy (IF 3.747): 2
Annals of Surgery (IF 9.203): 1
Molecular Cancer Research (IF 4.633): 1
Gut: Microbes (IF 7.823): 1
European Journal of Gastroenterology and Hepatology (IF 2.198): 1
International Journal of Surgery (IF 3.158): 1
Clinical Liver Disease (IF 13.246): 6
Texas Heart Institute Journal (IF 0.758): 1
Helicobacter (IF 3.352): 3
Optics Letter (IF 3.589): 1
Cancer Prevention Research (Philadelphia) (IF 4.444): 1
American Journal of Infection Control (IF 2.211): 1
JCO Clinical Cancer Informatics (IF 20.892): 1
PLoS One (IF 2.776): 1
New England Journal of Medicine (IF 70.670): 1
Nutrients (IF 4.171): 1
Cancer (Basel) (IF 6.072): 1
Advances in Experimental Medicine and Biology (IF 2.126): 1
HONORS AND AWARDS

Anandasabapathy, Sharmila, M.D.
- 2019 Castle Connolly List of Top Doctors
- 2019 Women of Excellence at Baylor College of Medicine
- Role Model in the Field of GI Cancer Detection Research

Bradford, Andrea, Ph.D.
- Honored by Society of Health Psychology

El-Serag, Hashem, M.D.
- 2019 Castle Connolly List of Top Doctors
- Clarivate Analytics 2018 Highly Cited Researchers List
- President of the American Gastroenterological Association
- Guideline Creators for “Behavioral Medicine Management of Irritable Bowel Syndrome: A Referral Toolkit for Gastroenterology Providers”

Estes, Mary, M.D.
- Fellow by the National Academy of Inventors

Gould Suarez, Milena, M.D.
- Selection Committee for Baylor’s Norton Rose Fulbright Faculty Excellence Award
- Reappointed as a PPS I/II Facilitator

Graham, David, M.D.
- 2019 Castle Connolly List of Top Doctors

Hou, Jason, M.D.
- 2019 Castle Connolly List of Top Doctors

Jarbrink-Sehgal, Maria, M.D.
- Receives Ph.D. degree from Karolinska Institute
- Guideline Creators for “Behavioral Medicine Management of Irritable Bowel Syndrome: A Referral Toolkit for Gastroenterology Providers”

Kaur, Manreet, M.D.
- 2019 Castle Connolly List of Top Doctors

Ketwaroo, Gyanprakash, M.D.
- Vice Chair Group for Quality Improvement and Innovations
- 2019-2020 AGA Future Leaders Program
Khalaf, Natalia, M.D.

- 2018 Young Investigator Grant Award from American Pancreatic Association

Mindikoglu, Ayse, M.D.

- Fellow of American Association for the Study of Liver Diseases (FAASLD) Designation

Othman, Mohamed, M.D.

- Special Section Editor for Focal Points Section of Gastrointestinal Endoscopy

Patel, Kalpesh, M.D.

- New Director of Advanced Endoscopy Program
- 2019 Castle Connolly List of Top Doctors

Qureshi, Waqar, M.D.

- Panelist at “Video Night with Endoscopy Experts”
- 2018 Texas Super Doctors
- Course Director for American Society for Gastrointestinal Endoscopy at DDW
- 2019 Castle Connolly List of Top Doctors

Schwartz, Jim, M.D.

- 2019 Castle Connolly List of Top Doctors

Sealock, Robert, M.D.

- Early Career Faculty Award for Excellence in Patient Care

Shukla, Richa, M.D.

- 2019 Women of Excellence at Baylor College of Medicine
- “That’s the Way Player of the Month” Award from BCM Faculty Group
- Selected to attend AGA Women’s Leadership Conference

Vierling, John, M.D.

- 2019 Castle Connolly List of Top Doctors

PRESS

Agarwal, Suneal, M.D.

- MedPage Today, “PPIs cut upper GI bleeds from anticoagulants.” (Dec 2018)

Anandasabapathy, Sharmila, M.D.


Bradford, Andrea, Ph.D.


El-Serag, Hashem, M.D.

- Interviewed on Fox 26 news. (July 2018)
• MegPage Today, “Houston consensus shrinks gaps in H. pylori management.” (July 2018)
• M.D.Link, “Liver liver cancer risk seen with tenofovir treatment of chronic hepatitis B.” (Oct 2018)

Estes, Mary, M.D.
• BCM News, “Mother’s milk influences neonatal rotavirus infection.” (Nov 2018)
• Science Daily, “Sugars and microbiome in mother’s milk influences neonatal rotavirus infection.” (Nov 2018)
• Med India, “Sugars in breast milk influences neonatal rotavirus infection.” (Nov 2018)
• UC San Diego Health News, “Complex sugars and microbiome in mother’s milk influence neonatal rotavirus infection.” (Nov 2018)
• BCM From The Labs, “Image of the Month: Assembling a rotavirus factory.” (Jan 2019)

Graham, David, M.D.
• The Times of Israel, “Redhill gets added backwind for drug to treat Crohn’s disease.” (Oct 2018)

Hou, Jason, M.D.

Kanwal, Fasiha, M.D.
• The ASCO Post, “Nonalcoholic Fatty Liver Disease May Be Risk Factor for Liver Cancer.” (Aug 2018)
• Reuters, “Severe fatty liver disease boosts risk for liver cancer.” (Sept 2018)

Kaur, Manreet, M.D.

Natarajan, Yamini, M.D.
• MedPage Today, “DAAs best for cutting CVD risk in HCV.” (Nov 2019)
• AGA Perspectives, “My experiences during AGA’s Advocacy Day: Facilitating change” (Dec 2018)
• Silver Sneakers, “5 healthy foods that can upset your stomach.” (Mar 2019)

Qureshi, Waqar, M.D.
• Key note speaker at Crusaders for Colon Cancer
• BCM Momentum, “Colon polyps: Detection is key to preventing cancer.” (Mar 2019)

Shah, Rajesh, M.D.
• MedPage Today, “Colectomy may boost diabetes risk.” (Nov 2018)

Shukla, Richa, M.D.
• MDEdge.com, “Thiopurines linked to zoster in IBD patients.” (Dec 2018)

Sussman, Norman, M.D.
• Featured in Baylor St. Luke’s Medical Center “Daily Update” (Jan 2019)